Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
Vericel (NASDAQ:VCEL) will report fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026.
Management will host a conference call and webcast at 8:30 a.m. ET. Presentation slides will be available on the Investor Relations website and a replay will be available through February 26, 2027. Telephone participants may dial 800-330-6730 or +1-312-471-1351 with passcode 227995.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VCEL declined 1.91%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VCEL is down 2.7% with light volume. Peers show mostly smaller declines: ARDX -1.09%, AUPH -0.62%, MNKD -1.37%, MESO -0.44%, while CDTX is roughly flat at +0.03%, suggesting a stock-specific move rather than a coordinated sector reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Prelim 2025 results | Positive | +1.3% | Preliminary 2025 revenue, margin and cash updates ahead of full results. |
| Jan 06 | JPM conference presentation | Positive | +6.1% | Announcement of presentation at 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 14 | Stephens conference appearance | Positive | +0.1% | Fireside chat at Stephens Investment Conference with webcast access for investors. |
| Nov 06 | Q3 2025 earnings | Positive | +4.2% | Record Q3 revenue, strong MACI growth, profitability and reaffirmed 2025 guidance. |
| Oct 23 | Earnings date announcement | Neutral | -1.2% | Scheduling of Q3 2025 earnings call and webcast with replay details. |
Recent news — especially earnings and financial updates — has typically seen the stock move in the same direction as the news tone, with positive fundamentals followed by positive price reactions.
Over the last few months, Vericel has delivered a series of positive fundamental updates. On Nov 6, 2025, record Q3 2025 earnings with $67.5M revenue and solid profitability coincided with a 4.17% gain. Preliminary 2025 results on Jan 13, 2026 highlighted ~$276M revenue and strong margins, with a 1.26% rise. Conference appearances in November 2025 and January 2026 also saw modest to strong gains. A prior earnings date announcement on Oct 23, 2025 had a small negative move, but overall reactions have aligned with generally constructive news.
Market Pulse Summary
This announcement schedules Vericel’s fourth-quarter and full-year 2025 results for February 26, 2026, following preliminary figures released on January 13, 2026 that highlighted strong revenue growth and improving profitability. Investors may focus on how final audited numbers compare to those preliminary estimates and on updates to guidance, margins, and cash. Recent regulatory filings, including the Q3 2025 10-Q and Form 4 insider transactions, provide additional context on the company’s financial position and insider activity ahead of the call.
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be available until February 26, 2027.
To participate by telephone, dial 800-330-6730 or +1-312-471-1351 if connecting from outside the U.S. When connected, please use passcode: 227995.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
When will Vericel (VCEL) announce Q4 and full-year 2025 results?
How can investors access Vericel (VCEL) Q4 2025 earnings webcast?
What are the phone details to join Vericel (VCEL) earnings call on February 26, 2026?
Will Vericel (VCEL) provide a replay of the February 26, 2026 webcast?
What will Vericel (VCEL) discuss during the February 26, 2026 call?
